Biota Pharmaceuticals Inc Stock Nasdaq
Stocks
US6295191091
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 119M 106M 98.31M 89.08M 167M 11.29B 170M 1.18B 463M 5.91B 447M 438M 18.85B | P/E 2026 * |
-3.06x | P/E 2027 * | -0.58x |
|---|---|---|---|---|---|
| Enterprise Value | 119M 106M 98.31M 89.08M 167M 11.29B 170M 1.18B 463M 5.91B 447M 438M 18.85B | EV / Sales 2026 * |
1x | EV / Sales 2027 * | 50.7x |
| Free-Float |
98.52% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biota Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 2024-03-17 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-02-29 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 2025-05-18 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 2021-04-20 |
William Watson
BRD | Director/Board Member | 76 | 2022-08-03 |
Elaine Heron
BRD | Director/Board Member | 79 | 2021-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.79% | -6.16% | +49.32% | +74.50% | 65.83B | |
| +1.92% | +10.35% | +13.02% | +87.74% | 51.87B | |
| +6.91% | +8.57% | +6.88% | +72.12% | 51.2B | |
| +0.74% | +2.75% | +26.31% | +45.29% | 43.76B | |
| +3.87% | +10.15% | +20.69% | +132.73% | 42.09B | |
| +7.91% | +4.30% | +263.91% | +602.72% | 39.04B | |
| -0.40% | +9.85% | +17.04% | +59.17% | 34B | |
| +3.84% | -2.34% | +39.18% | +8.57% | 25.2B | |
| +2.36% | +5.34% | +30.98% | +26.07% | 22.8B | |
| Average | +3.10% | +1.67% | +51.93% | +123.21% | 41.76B | |
| Weighted average by Cap. | +3.05% | +2.01% | +50.22% | +125.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 119M 106M 97.84M 88.66M 167M 11.24B 169M 1.17B 461M 5.88B 445M 436M 18.76B | 2.35M 2.09M 1.94M 1.76M 3.3M 223M 3.36M 23.26M 9.14M 117M 8.81M 8.63M 372M |
| Net income | -47.2M -42.01M -38.94M -35.28M -66.31M -4.47B -67.42M -467M -184M -2.34B -177M -173M -7.46B | -222M -197M -183M -166M -311M -20.99B -317M -2.19B -862M -10.99B -831M -814M -35.04B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
